281 related articles for article (PubMed ID: 30194068)
1. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.
Caruso JA; Duong MT; Carey JPW; Hunt KK; Keyomarsi K
Cancer Res; 2018 Oct; 78(19):5481-5491. PubMed ID: 30194068
[TBL] [Abstract][Full Text] [Related]
2. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
Duong MT; Akli S; Wei C; Wingate HF; Liu W; Lu Y; Yi M; Mills GB; Hunt KK; Keyomarsi K
PLoS Genet; 2012; 8(3):e1002538. PubMed ID: 22479189
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.
Akli S; Zheng PJ; Multani AS; Wingate HF; Pathak S; Zhang N; Tucker SL; Chang S; Keyomarsi K
Cancer Res; 2004 May; 64(9):3198-208. PubMed ID: 15126360
[TBL] [Abstract][Full Text] [Related]
4. Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.
Doostan I; Karakas C; Kohansal M; Low KH; Ellis MJ; Olson JA; Suman VJ; Hunt KK; Moulder SL; Keyomarsi K
Clin Cancer Res; 2017 Dec; 23(23):7288-7300. PubMed ID: 28947566
[No Abstract] [Full Text] [Related]
5. Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation.
Delk NA; Hunt KK; Keyomarsi K
Cancer Res; 2009 Apr; 69(7):2817-25. PubMed ID: 19318554
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.
Akli S; Bui T; Wingate H; Biernacka A; Moulder S; Tucker SL; Hunt KK; Keyomarsi K
Clin Cancer Res; 2010 Feb; 16(4):1179-90. PubMed ID: 20145171
[TBL] [Abstract][Full Text] [Related]
7. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.
Bagheri-Yarmand R; Nanos-Webb A; Biernacka A; Bui T; Keyomarsi K
Cancer Res; 2010 Jun; 70(12):5085-95. PubMed ID: 20530684
[TBL] [Abstract][Full Text] [Related]
8. Why are the truncated cyclin Es more effective CDK2 activators than the full-length isoforms?
Rath SL; Senapati S
Biochemistry; 2014 Jul; 53(28):4612-24. PubMed ID: 24947816
[TBL] [Abstract][Full Text] [Related]
9. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27.
Wingate H; Zhang N; McGarhen MJ; Bedrosian I; Harper JW; Keyomarsi K
J Biol Chem; 2005 Apr; 280(15):15148-57. PubMed ID: 15708847
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression.
Wingate H; Puskas A; Duong M; Bui T; Richardson D; Liu Y; Tucker SL; Van Pelt C; Meijer L; Hunt K; Keyomarsi K
Cell Cycle; 2009 Apr; 8(7):1062-8. PubMed ID: 19305161
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer.
Akli S; Zhang XQ; Bondaruk J; Tucker SL; Czerniak PB; Benedict WF; Keyomarsi K
Cell Cycle; 2012 Apr; 11(7):1468-76. PubMed ID: 22441703
[TBL] [Abstract][Full Text] [Related]
12. Depletion of SUMO ligase hMMS21 impairs G1 to S transition in MCF-7 breast cancer cells.
Ni HJ; Chang YN; Kao PH; Chai SP; Hsieh YH; Wang DH; Fong JC
Biochim Biophys Acta; 2012 Dec; 1820(12):1893-900. PubMed ID: 22906975
[TBL] [Abstract][Full Text] [Related]
13. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2.
Chu I; Sun J; Arnaout A; Kahn H; Hanna W; Narod S; Sun P; Tan CK; Hengst L; Slingerland J
Cell; 2007 Jan; 128(2):281-94. PubMed ID: 17254967
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer.
Karakas C; Biernacka A; Bui T; Sahin AA; Yi M; Akli S; Schafer J; Alexander A; Adjapong O; Hunt KK; Keyomarsi K
Am J Pathol; 2016 Jul; 186(7):1900-1912. PubMed ID: 27182644
[TBL] [Abstract][Full Text] [Related]
15. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.
Alexander A; Karakas C; Chen X; Carey JP; Yi M; Bondy M; Thompson P; Cheung KL; Ellis IO; Gong Y; Krishnamurthy S; Alvarez RH; Ueno NT; Hunt KK; Keyomarsi K
Oncotarget; 2017 Feb; 8(9):14897-14911. PubMed ID: 28107181
[TBL] [Abstract][Full Text] [Related]
16. Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition.
Flores O; Wang Z; Knudsen KE; Burnstein KL
Endocrinology; 2010 Mar; 151(3):896-908. PubMed ID: 20147522
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification.
Bagheri-Yarmand R; Biernacka A; Hunt KK; Keyomarsi K
Cancer Res; 2010 Jun; 70(12):5074-84. PubMed ID: 20530685
[TBL] [Abstract][Full Text] [Related]
18. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E.
Akli S; Van Pelt CS; Bui T; Meijer L; Keyomarsi K
Cancer Res; 2011 May; 71(9):3377-86. PubMed ID: 21385896
[TBL] [Abstract][Full Text] [Related]
19. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.
Hunt KK; Karakas C; Ha MJ; Biernacka A; Yi M; Sahin AA; Adjapong O; Hortobagyi GN; Bondy M; Thompson P; Cheung KL; Ellis IO; Bacus S; Symmans WF; Do KA; Keyomarsi K
Clin Cancer Res; 2017 Jun; 23(12):2991-3002. PubMed ID: 27881578
[No Abstract] [Full Text] [Related]
20. Targeting low molecular weight cyclin E (LMW-E) in breast cancer.
Nanos-Webb A; Jabbour NA; Multani AS; Wingate H; Oumata N; Galons H; Joseph B; Meijer L; Hunt KK; Keyomarsi K
Breast Cancer Res Treat; 2012 Apr; 132(2):575-88. PubMed ID: 21695458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
